drugset / Trial / NCT02248805
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.
Timeline
- Start
- 2014-10
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGD007 | Protein / enzyme biologic | — | — |